Nonclinical Pharmacokinetics and Pharmacodynamics Characterization of Anti-CD79b/CD3 T Cell-Dependent Bispecific Antibody Using a Surrogate Molecule: A Potential Therapeutic Agent for B Cell Malignancies
The T cell-dependent bispecific (TDB) antibody, anti-CD79b/CD3, targets CD79b and CD3 cell-surface receptors expressed on B cells and T cells, respectively. Since the anti-CD79b arm of this TDB binds only to human CD79b, a surrogate TDB that binds to cynomolgus monkey CD79b (cyCD79b) was used for pr...
Saved in:
Main Authors: | Rajbharan Yadav (Author), Siddharth Sukumaran (Author), Tanja S. Zabka (Author), Jinze Li (Author), Amy Oldendorp (Author), Gary Morrow (Author), Arthur Reyes (Author), Melissa Cheu (Author), Jessica Li (Author), Jeffrey J. Wallin (Author), Siao Tsai (Author), Laura Sun (Author), Peiyin Wang (Author), Diego Ellerman (Author), Christoph Spiess (Author), Andy Polson (Author), Eric G. Stefanich (Author), Amrita V. Kamath (Author), Meric A. Ovacik (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CD34 and CD79a immunopositivity in megakaryocytes
by: Pavithra Ayyanar, et al.
Published: (2021) -
Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG1 antibodies
by: Wen-Ting K. Tsai, et al.
Published: (2024) -
Bispecific T cell engagers targeting CD20/CD3 in B-cell lymphoma: latest updates from 2023 EHA annual meeting
by: Shenhe Jin, et al.
Published: (2023) -
An integrated approach for characterizing immunogenic responses toward a bispecific antibody
by: Sivan Cohen, et al.
Published: (2021) -
Lower proportion of CD19+IL-10+ and CD19+CD24+CD27+ but not CD1d+CD5+CD19+CD24+CD27+ IL-10+ B cells in children with autoimmune thyroid diseases
by: Karolina Stożek, et al.
Published: (2020)